Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
Shari B BrosnahanXian Jie Cindy ChengJuri ChungDiana AltshulerShahidul IslamSarun V ThomasMegan D WinnerAllison A GrecoJasmin DiversPeter SpieglerDaniel H StermanSam ParniaPublished in: The Annals of pharmacotherapy (2021)
Combination of tocilizumab and corticosteroids was associated with improved 28-day survival when compared with corticosteroids alone. Modification of steroid dosing strategy as well as steroid type may further optimize therapeutic effect of the COVID-19 treatment.
Keyphrases
- high dose
- low dose
- coronavirus disease
- sars cov
- respiratory failure
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- prognostic factors
- stem cell transplantation
- cardiovascular disease
- cardiovascular events
- type diabetes
- intensive care unit
- respiratory syndrome coronavirus
- patient reported outcomes
- replacement therapy